At Biocon, we are driven by our passion to develop research - driven cutting edge therapies. Our tryst with innovation has enabled us to address the relatively unmet needs of our patients through differentiated products in challenging therapeutic spaces.

We have earned the trust of patients and doctors through our products that are safe, efficacious and affordable. We are constantly engaged in pursuit of excellence to find solutions that heal the world.

Biocon is India's largest and fully-integrated, innovation-led biopharmaceutical company. We are committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer.

Through innovative products and research services we are constantly enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. We have successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'.

Some of our key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb? (Trastuzumab), BIOMAb-EGFR? (Nimotuzumab) and ALZUMAb?(Itolizumab), a 'first in class' anti-CD6 monoclonal antibody.